Edition:
United States

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

27.24USD
12:59pm EST
Change (% chg)

$0.38 (+1.40%)
Prev Close
$26.86
Open
$26.90
Day's High
$27.86
Day's Low
$26.90
Volume
9,326
Avg. Vol
77,401
52-wk High
$35.48
52-wk Low
$21.27

Select another date:

Fri, Nov 9 2018

Mylan and Theravance's COPD treatment gets FDA approval

Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

UPDATE 2-Mylan and Theravance's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Mylan and Theravance Biopharma's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Select another date: